Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain.

ABSTRACT: Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the perspective of the Spanish National Health System. Analyses were based on the EMBRACA clinical trial and the model was constructed according to "partitioned survival analysis". Two scenarios were considered in order to compare talazoparib with the alternatives of capecitabine, vinorelbine and eribulin: 1. Chemotherapy in patients pre-treated with anthracyclines/taxanes and, 2. A second- and subsequent-line treatment option. Treatment types following relapse were recorded in the mentioned clinical trial. The effectiveness measure used was quality-adjust

SUBMITTER: Olry de Labry Lima A 

PROVIDER: S-EPMC8099594 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature